4//SEC Filing
Londei Marco 4
Accession 0001209191-19-003996
CIK 0001370053other
Filed
Jan 15, 7:00 PM ET
Accepted
Jan 16, 7:09 PM ET
Size
13.9 KB
Accession
0001209191-19-003996
Insider Transaction Report
Form 4
ANAPTYSBIO INCANAB
Londei Marco
Chief Medical Officer
Transactions
- Exercise/Conversion
Employee Stock Option (Right to Buy)
2019-01-15−19,075→ 51,148 totalExercise: $6.93Exp: 2025-08-13→ Common Stock (19,075 underlying) - Sale
Common Stock
2019-01-15$69.29/sh−4,181$289,686→ 37,271 total - Gift
Common Stock
2018-12-26−122,500→ 22,377 total - Exercise/Conversion
Common Stock
2019-01-15$6.93/sh+19,075$132,190→ 41,452 total - Sale
Common Stock
2019-01-15$70.04/sh−14,894$1,043,195→ 22,377 total
Footnotes (6)
- [F1]Represents the number of shares of Issuer's common stock that were donated as a charitable contribution. The reporting person does not exercise voting or dispositive powers, directly or indirectly, over the donated shares following this transfer.
- [F2]The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person.
- [F3]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $68.63 to $69.60 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $69.63 to $70.37 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F5]The stock option vested and became exercisable as to 25% of the shares subject to the option on August 13, 2016, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.
- [F6]In addition to the remaining options to purchase 51,148 shares of common stock as set forth in Table II above, the Reporting Person also holds (i) additional options to purchase up to an aggregate of 148,060 shares of common stock, which options vest according to their terms, and (ii) 22,377 shares of common stock held directly.
Documents
Issuer
ANAPTYSBIO INC
CIK 0001370053
Entity typeother
Related Parties
1- filerCIK 0001654500
Filing Metadata
- Form type
- 4
- Filed
- Jan 15, 7:00 PM ET
- Accepted
- Jan 16, 7:09 PM ET
- Size
- 13.9 KB